On May 12, 2025, President Donald Trump signed an executive order related to drug prices in the Roosevelt Room of the White House. The event was attended by Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, and Health and Human Services Secretary Robert F. Kennedy Jr. The executive order aims to address the issue of high drug prices in the United States. The signing ceremony underscored the administration's focus on healthcare reforms, particularly in the realm of pharmaceutical pricing. The presence of key healthcare officials highlighted the collaborative effort to implement changes in drug pricing policies. The executive order is part of a broader initiative to make healthcare more affordable for American citizens. The administration has been working on various measures to reduce the financial burden on patients, with drug pricing being a significant component. The signing of this order marks a step forward in the ongoing efforts to reform the healthcare system. The outcomes and specific details of the executive order are yet to be fully realized, but the event signifies a commitment to addressing one of the most pressing issues in American healthcare. The administration continues to work on implementing the changes outlined in the order, with the goal of providing more affordable healthcare options for the public.